The invention relates to the design and synthesis of 3-arylidene-anabaseine compounds that exhibit enhanced selectivity toward alpha7 nicotinic receptors. The compounds are expected to be useful in treating a wide variety of conditions, including neurodegenerative conditions such as Alzheimer's Disease, neurodevelopmental diseases such as schizophrenia, and certain peripherally located inflammations mediated by macrophage infiltration.
The invention relates to the design and synthesis of 3-arylidene-anabaseine compounds that exhibit enhanced selectivity toward alpha7 nicotinic receptors. The compounds are expected to be useful in treating a wide variety of conditions, including neurodegenerative conditions such as Alzheimer's Disease, neurodevelopmental diseases such as schizophrenia, and certain peripherally located inflammations mediated by macrophage infiltration.
[EN] The invention relates to the design and synthesis of 3-arylidene-anabaseine compounds that exhibit enhanced selectivity toward alpha7 nicotinic receptors. The compounds are expected to be useful in treating a wide variety of conditions, including neurodegenerative conditions such as Alzheimer's Disease, neurodevelopmental diseases such as schizophrenia, and certain peripherally located inflammations mediated by macrophage infiltration. [FR] L'invention se rapporte à la structure et la synthèse de composés 3-arylidène-anabaséine qui présentent une sélectivité renforcée à l'égard des récepteurs nicotiniques alpha 7. On peut s'attendre à ce que ces composés soient utiles lors du traitement de nombreuses variétés de troubles, dont les affections neurodégénératives telles que la maladie d'Alzheimer, les troubles neurodéveloppementaux tels que la schizophrénie, et certaines inflammations périphériques induites par une infiltration par macrophages.